1.4 Cardiovascular Pharmacology & Cardiac Medications

Cardiovascular Pharmacology & Cardiac Medications

Patients undergoing resting electrocardiograms, continuous telemetry monitoring, and exercise stress testing are frequently taking multiple cardiovascular medications. Because these therapeutic agents deliberately alter cardiac electrophysiology, autonomic tone, ion channel kinetics, and systemic hemodynamics, certified cardiographic technicians must master their mechanisms of action, clinical indications, and signature electrocardigraphic manifestations. Distinguishing normal, therapeutic medication effects (such as PR prolongation from beta-blockers or "scooped" ST depression from digoxin) from acute myocardial ischemia, electrolyte toxicity, or life-threatening drug-induced arrhythmias is a primary competency assessed on the CCI CCT examination.

---

1. Fundamentals of Pharmacological Cardiac Modulation

Cardiovascular drugs exert actions on the heart that are classified by four cardinal physiological descriptors:

• Chronotropic Effects: Alterations in heart rate (SA node firing frequency). Positive chronotropes increase heart rate; negative chronotropes decrease heart rate.
• Dromotropic Effects: Alterations in conduction velocity through specialized cardiac tissue, particularly the Atrioventricular (AV) node. Negative dromotropes slow AV conduction and prolong the PR interval.
• Inotropic Effects: Alterations in myocardial contractile force. Positive inotropes increase stroke volume and contractility; negative inotropes decrease contractile force.
• Bathmotropic Effects: Alterations in myocardial excitability and threshold for action potential generation.

---

2. Vaughan-Williams Antiarrhythmic Classification System

Antiarrhythmic agents are traditionally classified into five major groups based on their primary cellular electrophysiological mechanism and target ion channels.

---

3. Detailed Class Analysis & Clinical ECG Manifestations

Class I: Sodium Channel Blockers

• Class Ia (Procainamide, Quinidine): By slowing conduction velocity and delaying repolarization, Class Ia agents cause widening of the QRS complex and prolongation of the QTc interval. Technicians must monitor QTc closely; a QTc exceeding 500 ms creates a high-risk substrate for Torsades de Pointes (a life-threatening polymorphic ventricular tachycardia characterized by twisting QRS complexes around the isoelectric line).
• Class Ib (Lidocaine, Mexiletine): Lidocaine is administered intravenously exclusively for ventricular tachyarrhythmias, particularly in acute coronary syndromes. Because it selectively binds to ischemic cardiac cells and rapidly dissociates, it does not prolong the QRS complex at therapeutic concentrations.
• Class Ic (Flecainide, Propafenone): Flecainide exerts the most potent sodium channel blockade without altering repolarization duration. It causes profound QRS widening. The landmark Cardiac Arrhythmia Suppression Trial (CAST) demonstrated that Class Ic drugs increase mortality in patients with prior myocardial infarction or ischemic heart disease; thus, they are reserved for patients with structurally normal hearts.

Class II: Beta-Adrenergic Blockers (Beta-Blockers)

Beta-blockers competitively inhibit sympathetic beta-1 receptors in the myocardium and cardiac conduction tissue.

• Naming Recognition: Generic beta-blockers uniformly end in the suffix "-olol" (e.g., Metoprolol, Atenolol, Propranolol, Esmolol, Bisoprolol, Carvedilol).
• Electrophysiological Effects: Slows SA node automaticity (negative chronotropy) and AV node conduction (negative dromotropy).
• ECG Manifestations: Resting sinus bradycardia (HR < 60 bpm) and PR interval prolongation (first-degree AV block).
• Stress Testing Impact: Beta-blockers prevent normal sympathetic heart rate acceleration during exertion, producing a blunted heart rate response. Patients may fail to achieve their age-predicted Target Heart Rate (THR = 220 - Age), compromising diagnostic yield unless the medication is withheld per laboratory protocol (typically 24–48 hours prior to diagnostic exercise stress testing).
• Clinical Precautions: Non-selective beta-blockers (e.g., Propranolol) block beta-2 receptors in bronchial smooth muscle, potentially precipitating severe bronchospasm in patients with asthma or severe COPD.

Class III: Potassium Channel Blockers

Class III agents block outward potassium currents during Phase 3 of the cardiac action potential, delaying repolarization across the myocardium.

• Amiodarone (Cordarone): A broad-spectrum antiarrhythmic possessing Class I, II, III, and IV properties. It is highly effective for both supraventricular and ventricular arrhythmias.
• ECG Manifestations: Causes QTc prolongation, T-wave flattening, and prominent U waves.
• Clinical Exam Highlights: Amiodarone has an extraordinarily long elimination half-life (30 to 60 days) and extensive tissue distribution. It carries significant organ toxicity risks, including pulmonary fibrosis, thyroid dysfunction (hypothyroidism or hyperthyroidism due to high iodine content), corneal microdeposits, hepatotoxicity, and slate-blue skin discoloration.
• Sotalol & Dofetilide: Require inpatient telemetry monitoring during initiation to track QTc prolongation and prevent Torsades de Pointes.

Class IV: Calcium Channel Blockers (CCBs)

Calcium channel blockers inhibit L-type voltage-gated calcium channels, but are divided into two distinct sub-classes:

1. Non-Dihydropyridines (Diltiazem, Verapamil): Exert selective action on cardiac nodal tissue and myocardium. They slow SA node firing and AV node conduction while reducing contractility.
   • ECG Impact: Sinus bradycardia, PR prolongation, and AV block. Frequently utilized for rate control in rapid Atrial Fibrillation or Atrial Flutter.
   • Contraindication: Contraindicated in patients with severe left ventricular systolic dysfunction (reduced ejection fraction) due to negative inotropic depression.
2. Dihydropyridines (Amlodipine, Nifedipine, Felodipine): Act selectively on vascular smooth muscle to cause arterial vasodilation, reducing afterload and blood pressure, with negligible direct effects on cardiac conduction.
   • ECG Impact: May cause reflex sinus tachycardia due to sudden peripheral vasodilation.

---

4. Digitalis Glycosides: Digoxin (Lanoxin)

Digoxin is a cardiac glycoside used in heart failure and atrial fibrillation.

• Mechanism of Action: Inhibits the sarcolemmal $Na^+/K^+$-ATPase pump, resulting in increased intracellular sodium, which secondarily reduces calcium efflux via the $Na^+/Ca^{2+}$ exchanger. The resulting intracellular calcium accumulation increases contractile force (positive inotropism). Simultaneously, digoxin increases central vagal tone, slowing SA node automaticity and AV node conduction (negative chronotropism and dromotropism).
• Therapeutic ECG Pattern ("Digitalis Effect"): At therapeutic serum concentrations (0.5–2.0 ng/mL), digoxin produces characteristic baseline ECG modifications that are normal therapeutic drug manifestations, NOT signs of ischemia or toxicity:
  • "Scooped" or "Sagging" ST-Segment Depression: ST segments exhibit a smooth, concave downward slope, often described as resembling a "hockey stick" or "Salvador Dalí mustache."
  • Shortened QTc interval.
  • T-wave flattening, inversion, or biphasic T waves.
  • Mild PR interval prolongation.
• Digoxin Toxicity & ECG Arrhythmias: Digoxin has a narrow therapeutic index. Toxicity is markedly potentiated by hypokalemia (low serum potassium allows digoxin to bind more extensively to the $Na^+/K^+$-ATPase pump).
  • ECG Signs of Toxicity: Paroxysmal Atrial Tachycardia (PAT) with AV Block (classic exam finding!), Mobitz type I or complete AV block, junctional escape rhythms, frequent PVCs, ventricular bigeminy, and bidirectional ventricular tachycardia.
  • Non-cardiac Symptoms: Anorexia, nausea, vomiting, confusion, and visual disturbances including yellow-green color halos (xanthopsia).

---

5. Vasodilators & Nitrates

Nitrates (Sublingual Nitroglycerin, Isosorbide Mononitrate / Dinitrate)

• Mechanism: Converted to nitric oxide (NO), stimulating cGMP production and causing vascular smooth muscle relaxation.
• Hemodynamic Impact: Nitrates primarily dilate systemic veins, drastically decreasing venous return to the right atrium (reduced preload). Decreased preload reduces end-diastolic ventricular wall tension and myocardial oxygen demand. To a lesser degree, nitrates dilate coronary arteries to relieve coronary spasm.
• Clinical Indications: Acute angina pectoris, ischemic chest pain, acute heart failure, and hypertensive crises.
• ECG & Clinical Manifestations: May cause reflex sinus tachycardia secondary to sudden blood pressure drop.
• Critical Exam Caution: Nitrates cause profound hypotension and severe throbbing headaches. Concomitant administration of Nitroglycerin with Phosphodiesterase-5 (PDE-5) inhibitors (e.g., Sildenafil/Viagra, Tadalafil/Cialis) within 24–48 hours is strictly contraindicated due to the risk of catastrophic, refractory hypotension and fatal shock.

---

6. RAAS Inhibitors & Antihypertensives

ACE Inhibitors & Angiotensin Receptor Blockers (ARBs)

• ACE Inhibitors (Suffix "-pril": Lisinopril, Enalapril, Ramipril, Captopril): Inhibit Angiotensin-Converting Enzyme, preventing conversion of Angiotensin I to Angiotensin II.
• ARBs (Suffix "-sartan": Losartan, Valsartan, Candesartan): Block Angiotensin II type 1 ($AT_1$) receptors directly.
• Hemodynamic Effects: Arterial vasodilation decreases systemic vascular resistance (reduced afterload), reducing left ventricular workload. They inhibit aldosterone secretion and prevent adverse ventricular remodeling following myocardial infarction.
• Key Side Effects: ACE inhibitors cause a persistent dry, non-productive cough in 10–15% of patients due to bradykinin accumulation. Both classes can cause hyperkalemia by decreasing aldosterone-mediated renal potassium excretion.

---

7. Diuretics & Electrolyte-Induced ECG Abnormalities

Diuretics promote renal fluid excretion to reduce blood volume, systemic venous pressure, and peripheral or pulmonary edema in hypertension and heart failure.

---

8. Antiplatelets vs. Anticoagulants

Cardiographic technicians must distinguish between antiplatelet and anticoagulant agents, as both are referred to colloquially as "blood thinners" but target completely separate hematological pathways.

Antiplatelet Agents

• Mechanism: Inhibit platelet activation, recruitment, and aggregation.
• Drugs: Aspirin (irreversible COX-1 inhibitor), Clopidogrel (Plavix), Prasugrel (Effient), Ticagrelor (Brilinta) (P2Y12 ADP receptor antagonists).
• Indications: Primary and secondary prevention of acute myocardial infarction, acute coronary syndromes (STEMI/NSTEMI), and prevention of coronary stent thrombosis following percutaneous coronary intervention (PCI).

Anticoagulants

• Mechanism: Interfere with specific enzymatic factors within the intrinsic, extrinsic, and common coagulation cascades to prevent fibrin clot formation.
• Drugs:
  • Unfractionated Heparin (UFH) & LMWH (Enoxaparin/Lovenox): Potentiate Antithrombin III, inhibiting Thrombin (Factor IIa) and Factor Xa.
  • Vitamin K Antagonists (Warfarin/Coumadin): Inhibit synthesis of vitamin K-dependent clotting factors (II, VII, IX, X). Requires routine INR monitoring (target 2.0–3.0).
  • Direct Oral Anticoagulants (DOACs - Apixaban/Eliquis, Rivaroxaban/Xarelto, Dabigatran/Pradaxa): Direct Factor Xa or thrombin inhibitors.
• Indications: Prevention of systemic thromboembolism in Atrial Fibrillation, deep vein thrombosis (DVT), pulmonary embolism (PE), and mechanical heart valves.
• Procedural Relevance: Technicians performing invasive procedures (e.g., cardiac catheterization or pacemaker implantation) must confirm discontinuation status to minimize severe hemorrhage or groin hematoma formation.